Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

3D Organotypic Culture Model to Study Components of ERK Signaling.

Chioni AM, Bajwa RT, Grose R.

Methods Mol Biol. 2017;1487:255-267.

PMID:
27924573
2.

Docetaxel rechallenge in metastatic castration-resistant prostate cancer: any place in the modern treatment scenario? An intention to treat evaluation.

Bracarda S, Caserta C, Galli L, Carlini P, Pastina I, Sisani M, Scali S, Hamzaj A, Derosa L, Felici A, Rossi M, Altavilla A, Chioni A, De Angelis V.

Future Oncol. 2015 Nov;11(22):3083-90. doi: 10.2217/fon.15.217. Epub 2015 Oct 5.

PMID:
26437324
3.

EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definition.

Rotella V, Fornaro L, Vasile E, Tibaldi C, Boldrini L, Chella A, D'Incecco A, Cirigliano G, Chioni A, Lupi C, Sensi E, Ginocchi L, Giovannelli S, Pennucci MC, Fontanini G, Baldini E.

J Exp Clin Cancer Res. 2014 Oct 11;33:77. doi: 10.1186/s13046-014-0077-6.

4.

The ins and outs of fibroblast growth factor receptor signalling.

Coleman SJ, Bruce C, Chioni AM, Kocher HM, Grose RP.

Clin Sci (Lond). 2014 Aug;127(4):217-31. doi: 10.1042/CS20140100. Review.

PMID:
24780002
5.

Nuclear translocation of FGFR1 and FGF2 in pancreatic stellate cells facilitates pancreatic cancer cell invasion.

Coleman SJ, Chioni AM, Ghallab M, Anderson RK, Lemoine NR, Kocher HM, Grose RP.

EMBO Mol Med. 2014 Apr;6(4):467-81. doi: 10.1002/emmm.201302698. Epub 2014 Feb 6.

6.

Identification of ZDHHC14 as a novel human tumour suppressor gene.

Yeste-Velasco M, Mao X, Grose R, Kudahetti SC, Lin D, Marzec J, Vasiljević N, Chaplin T, Xue L, Xu M, Foster JM, Karnam SS, James SY, Chioni AM, Gould D, Lorincz AT, Oliver RT, Chelala C, Thomas GM, Shipley JM, Mather SJ, Berney DM, Young BD, Lu YJ.

J Pathol. 2014 Apr;232(5):566-77. doi: 10.1002/path.4327. Epub 2014 Feb 8. Erratum in: J Pathol. 2014 Sep;234(1):134.

PMID:
24407904
7.

Fibroblast growth factor 22 is not essential for skin development and repair but plays a role in tumorigenesis.

Jarosz M, Robbez-Masson L, Chioni AM, Cross B, Rosewell I, Grose R.

PLoS One. 2012;7(6):e39436. doi: 10.1371/journal.pone.0039436. Epub 2012 Jun 21.

8.

FGFR1 cleavage and nuclear translocation regulates breast cancer cell behavior.

Chioni AM, Grose R.

J Cell Biol. 2012 Jun 11;197(6):801-17. doi: 10.1083/jcb.201108077. Epub 2012 Jun 4.

9.

Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients.

Pastina I, Giovannetti E, Chioni A, Sissung TM, Crea F, Orlandini C, Price DK, Cianci C, Figg WD, Ricci S, Danesi R.

BMC Cancer. 2010 Sep 27;10:511. doi: 10.1186/1471-2407-10-511.

10.

Protein kinase A and regulation of neonatal Nav1.5 expression in human breast cancer cells: activity-dependent positive feedback and cellular migration.

Chioni AM, Shao D, Grose R, Djamgoz MB.

Int J Biochem Cell Biol. 2010 Feb;42(2):346-58. doi: 10.1016/j.biocel.2009.11.021. Epub 2009 Dec 3.

PMID:
19948241
11.

Negative regulation of fibroblast growth factor 10 (FGF-10) by polyoma enhancer activator 3 (PEA3).

Chioni AM, Grose R.

Eur J Cell Biol. 2009 Jul;88(7):371-84. doi: 10.1016/j.ejcb.2009.01.004. Epub 2009 May 2.

12.

Organotypic modelling as a means of investigating epithelial-stromal interactions during tumourigenesis.

Chioni AM, Grose R.

Fibrogenesis Tissue Repair. 2008 Dec 11;1(1):8. doi: 10.1186/1755-1536-1-8.

13.

A novel adhesion molecule in human breast cancer cells: voltage-gated Na+ channel beta1 subunit.

Chioni AM, Brackenbury WJ, Calhoun JD, Isom LL, Djamgoz MB.

Int J Biochem Cell Biol. 2009 May;41(5):1216-27. doi: 10.1016/j.biocel.2008.11.001. Epub 2008 Nov 12.

14.

The role of fibroblast growth factor receptor 2b in skin homeostasis and cancer development.

Grose R, Fantl V, Werner S, Chioni AM, Jarosz M, Rudling R, Cross B, Hart IR, Dickson C.

EMBO J. 2007 Mar 7;26(5):1268-78. Epub 2007 Feb 15.

15.

Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer.

Ricci S, Boni G, Pastina I, Genovesi D, Cianci C, Chiacchio S, Orlandini C, Grosso M, Alsharif A, Chioni A, Di Donato S, Francesca F, Selli C, Rubello D, Mariani G.

Eur J Nucl Med Mol Imaging. 2007 Jul;34(7):1023-30. Epub 2007 Jan 23.

PMID:
17242920
16.

The neonatal splice variant of Nav1.5 potentiates in vitro invasive behaviour of MDA-MB-231 human breast cancer cells.

Brackenbury WJ, Chioni AM, Diss JK, Djamgoz MB.

Breast Cancer Res Treat. 2007 Jan;101(2):149-60. Epub 2006 Jul 13.

17.

A novel polyclonal antibody specific for the Na(v)1.5 voltage-gated Na(+) channel 'neonatal' splice form.

Chioni AM, Fraser SP, Pani F, Foran P, Wilkin GP, Diss JK, Djamgoz MB.

J Neurosci Methods. 2005 Sep 30;147(2):88-98.

PMID:
16111763
18.

Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis.

Fraser SP, Diss JK, Chioni AM, Mycielska ME, Pan H, Yamaci RF, Pani F, Siwy Z, Krasowska M, Grzywna Z, Brackenbury WJ, Theodorou D, Koyutürk M, Kaya H, Battaloglu E, De Bella MT, Slade MJ, Tolhurst R, Palmieri C, Jiang J, Latchman DS, Coombes RC, Djamgoz MB.

Clin Cancer Res. 2005 Aug 1;11(15):5381-9. Erratum in: Clin Cancer Res. 2005 Nov 15;11(22):8224.

19.

Increased dose-intensity of gemcitabine in advanced non small cell lung cancer (NSCLC): a multicenter phase II study in elderly patients from the "polmone toscano group" (POLTO).

Tibaldi C, Ricci S, Russo F, Bernardini I, Galli L, Chioni A, Orlandini C, Grosso AM, Pegna AL, Fabbri A, Innocenti F, Ferrari K, Tognarini L, Conte PF, Falcone A; POLTO group.

Lung Cancer. 2005 Apr;48(1):121-7. Epub 2004 Dec 10.

PMID:
15777979
20.

T-lymphocyte invasiveness: control by voltage-gated Na+ channel activity.

Fraser SP, Diss JK, Lloyd LJ, Pani F, Chioni AM, George AJ, Djamgoz MB.

FEBS Lett. 2004 Jul 2;569(1-3):191-4.

21.

Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens.

Ricci S, Galli L, Chioni A, Iannopollo M, Antonuzzo A, Francesca F, Vocaturo V, Selli C, Orlandini C, Conte P.

Cancer. 2002 Oct 1;95(7):1444-50.

22.

Hemispheric predominance of abnormal findings in electroencephalogram (EEG).

Gatzonis SD, Roupakiotis S, Kambayianni E, Politi A, Triantafyllou N, Mantouvalos V, Chioni A, Zournas Ch, Siafakas A.

Seizure. 2002 Oct;11(7):442-4.

23.

The usefulness of sleep and sleep deprivation as activating methods in electroencephalographic recording: contribution to a long-standing discussion.

Roupakiotis SC, Gatzonis SD, Triantafyllou N, Mantouvalos V, Chioni A, Zournas C, Siafakas A.

Seizure. 2000 Dec;9(8):580-4.

24.

Convulsive status epilepticus following abrupt high-dose benzodiazepine discontinuation.

Gatzonis SD, Angelopoulos EK, Daskalopoulou EG, Mantouvalos V, Chioni A, Zournas C, Siafakas A.

Drug Alcohol Depend. 2000 Apr 1;59(1):95-7.

PMID:
10706979
25.

A case of fever following antiepileptic treatment.

Gatzonis S, Laiaki A, Chioni A, Siafakas A, Zournas C, Mantouvalos V.

Seizure. 1999 May;8(3):187-8.

26.

Nonepileptic seizures.

Gatzonis SD, Siafakas A, Chioni A, Zournas C, Mantouvalos V.

Epilepsia. 1999 Mar;40(3):387. No abstract available.

27.

External ophthalmoplegia with ragged-red fibres and acetylcholine receptor antibodies.

Mitsikostas D, Manta P, Kalfakis N, Chioni A, Ilias A, Liakopoulos D, Papageorgiou C.

Funct Neurol. 1995 Jul-Oct;10(4-5):209-15.

PMID:
8749048

Supplemental Content

Loading ...
Support Center